Pre-clinical assessment of anti-vascular drugs using quantitative dynamic contrast-enhanced MRI. (1st January 2012)

• Record Type: Journal Article
• Authors: Linnik, Inna V.; Williams, Steve R.; Davies, Karen E.; McGown, Alan T.; Hadfield, John A.; Buckley, David L.
• Is Part Of: International journal of medical engineering and informatics. Volume 4:Number 4(2012)
• Page Start: 362
• Page End: 372
• Publication Date: 2012-01-01
• Subjects: anti-cancer agent -- dynamic contrast-enhanced MRI -- tumour model -- radiation- induced fibrosarcoma; 610.2805
• Languages: English
• ISSNs: 1755-0653

Abstract

The effect of novel anti-cancer agents on the vascular properties of radiation-induced fibrosarcomas in C3H-strain mice was evaluated in vivo using dynamic contrast-enhanced (DCE) MRI. A T 1 -weighted volume acquisition was used to obtain DCE-MRI data. Pre-contrast T 1 measurements and the contrast agent arterial input function were used to estimate the volume transfer constant (K trans ) and extravascular extracellular volume fraction (ve ). Five novel combretastatin analogues, combretastatin A-4 (CA-4) and hazelnut oil (vehicle) were tested for their effect 24 hours after administration on the tumours. Three of the five agents and the positive control (CA-4), significantly decreased tumour K trans and ve : K trans for CA-4 by 72%; fluorocombretastatin by 75%; methylcombretastatin by 68%; and ve by 40% for methylcombretastatin and 75% for the combretastatin quinone. These agents were recommended for further consideration. These results suggest that DCE-MRI may be a useful tool for pre-clinical evaluation of anti-cancer drugs.